Search

everythinglearnresearchcommunity

for

Search:↓

The trial aims to test a new treatment for hair loss in young men using stem cell-derived vesicles.

New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.

In June 2019, the stem cell research field saw major progress, including new clinical trials, FDA approvals, and industry collaborations.

Existing drugs, including a blood pressure medication, show promise as new treatments for influenza.

HIF-1A may aid hair growth, Backhousia citriodora improves skin, autologous cells stabilize hair loss, infrared thermography assesses alopecia, and a new treatment preserves hair.

Provenge extends prostate cancer survival by about 4 months.

In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.

Dutasteride effectively treats benign prostatic obstruction, improves urinary flow, reduces prostate size, and may prevent prostate cancer, but can cause sexual side effects.

Promising cancer treatments were found, but the manufacturer closed.

Obesity in the U.S. is largely influenced by diet and exercise, certain medications can improve heart procedures and hair growth, and major teaching hospitals have better patient outcomes.

A new protein linked to Alzheimer's was discovered, and a hair loss treatment showed effectiveness but had some sexual side effects.

Developing microRNA-based treatments is hard but has potential.

Evidence-based urology improved treatment and quality of life for conditions like BPH by shifting from surgery to effective medications like finasteride and dutasteride.

Dutasteride is effective and safe for treating common hair loss, and it's more potent than finasteride, leading to better hair growth and thickness.

Topical vasoconstrictors do not reduce chemotherapy effectiveness against leukemia in mice.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.

GI197111X is best dissolved in Capmul MCM for trials.

Higher levels of nidogen1 and type IV collagen are found in basal cell carcinoma compared to normal skin.

The document concludes that ERBB2 mutations are common in extramammary Paget disease and may respond to systemic treatments like cancer immunotherapy.

New treatments for Hepatitis C show promise but need more research to confirm their safety and effectiveness for clinical use.

Blocking the prolactin receptor might help treat various diseases, but more research is needed.

Lichen planus pigmentosus and fibrosing frontal alopecia in Colombia are likely different stages of the same disease.

Current treatments for hair loss from chemotherapy are limited, but new methods are being researched.

Doxil is an effective, modified chemotherapy drug with a unique toxicity profile and shows promise in treating certain cancers.

Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.

There are several promising treatments for hair loss, including dutasteride, latanoprost, ketoconazole shampoo, anti-androgens, laser/light treatment, and platelet-rich plasma, but more research is needed.

COVID-19 may cause hair loss, often after recovery, with androgenetic alopecia being the most common type.

The document concludes that various cosmetic and drug treatments are available for hirsutism, and some new drugs show promise.

Mice with too much sPLA₂-IIA have hair loss and poor wound healing due to abnormal hair growth and stem cell depletion.